WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has named Jesse Hall, M.D., as its new Chief Medical Officer. Dr. Hall brings decades of expertise in medical and clinical development, particularly in immunology and antibody innovation, to help drive the company’s strategic focus on immuno-inflammatory product candidates.
“At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and has the right experience to lead our clinical organization,” said Dr. Neal Walker, CEO and Chair of Aclaris’ Board of Directors.
Dr. Hall expressed excitement about joining the company during what he described as a pivotal time. “The Company’s portfolio of potential best-in-class biologics and small molecules may help evolve clinical practice and improve the therapeutic experience of patients,” he stated.
Dr. Hall most recently served as Chief Medical Officer for AltruBio and has held prominent roles at companies such as Amgen, Abbott Labs, and AstraZeneca’s subsidiary, Ardea Biosciences. His track record includes contributing to the development and launch of leading therapies like HUMIRA® and PROLIA®.
Alongside his appointment, Dr. Hall has been granted stock options to purchase 510,000 shares and 145,500 restricted stock units under Aclaris’ 2024 Inducement Plan. These awards, designed to attract top talent, are tied to a vesting schedule over four years based on continued employment.
Dr. Hall’s appointment aims to advance Aclaris’ pipeline and deliver innovative solutions to address unmet medical needs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.